Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02362230 | Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy | terminated | Phase 2 | 26 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer |
| terminated |
| — |
| 226 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Jan 29, 2021 |
| clinicaltrials |
| NCT00090844 | Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer | terminated | Phase 2 | 49 | University of South FloridaOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02137837 | S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | terminated | Phase 3 | 37 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03055312 | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer(SYSUCC-007) | terminated | Phase 3 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT00700778 | Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations | terminated | N/A | 2 | Fox Chase Cancer CenterOTHER | 2 | Jan 25, 2021 | clinicaltrials |
| NCT00448266 | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | terminated | Phase 2 / Phase 3 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)(TRAXHER2) | terminated | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 12 | Jan 22, 2021 | clinicaltrials |
| NCT03429101 | A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | terminated | Phase 1 | 6 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2021 | clinicaltrials |
| NCT02659501 | Liposomal Bupivacaine in Implant Based Breast Reconstruction | terminated | N/A | 24 | Loma Linda UniversityOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT03292536 | Merestinib on Bone Metastases in Subjects With Breast Cancer | terminated | Phase 1 | 2 | University of UtahOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT04549584 | Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer(NEO-SMART) | terminated | — | 3 | Seoul National University HospitalOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT02936999 | Vitamin D Supplementation in Women With DCIS and/or LCIS | terminated | Early Phase 1 | 8 | Inova Health Care ServicesOTHER | 1 | Dec 16, 2020 | clinicaltrials |
| NCT02677714 | 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer | terminated | Phase 2 | 14 | Advanced Accelerator ApplicationsINDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT01495247 | Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 8, 2020 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | terminated | Phase 2 | 32 | GTxINDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT00796107 | A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer | terminated | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer(BATON-BC) | terminated | Phase 2 | 30 | AVEO Pharmaceuticals, Inc.INDUSTRY | 10 | Oct 27, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00138125 | Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | terminated | Phase 2 | 2 | Translational Oncology Research InternationalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00622466 | Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | terminated | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02433067 | Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer(CARDAPAC) | terminated | N/A | 89 | University of Franche-ComtéOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00751101 | Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer | terminated | Phase 2 | 24 | University of California, San FranciscoOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | terminated | Phase 1 | 2 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03718455 | Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes | terminated | N/A | 1 | Mayo ClinicOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00536939 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | terminated | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT00780676 | Personalized Treatment Selection for Metastatic Breast Cancer | terminated | Phase 2 | 97 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT03241810 | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer(SHERBOC) | terminated | Phase 2 | 22 | Elevation OncologyINDUSTRY | 6 | Sep 2, 2020 | clinicaltrials |
| NCT00756834 | Case Collection Study for Collecting Images for the Development and Validation of Computer Aided Detection Software | terminated | — | 135 | Siemens Medical SolutionsINDUSTRY | 1 | Aug 21, 2020 | clinicaltrials |
| NCT03430466 | Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer | terminated | Phase 2 | 1 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01225172 | Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors | terminated | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT00437294 | Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | terminated | Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 10, 2020 | clinicaltrials |
| NCT02055937 | Immediate Implant Breast Reconstruction(ISIS) | terminated | N/A | 53 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02893527 | Implementation and Evaluation of a Social Journey Accompanied in Breast Cancer Diagnosis (EPARS SEIN)(EPARS-SEIN) | terminated | N/A | 11 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT00112749 | Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer | terminated | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02685111 | Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) | terminated | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT00075673 | Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer | terminated | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00740961 | Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer | terminated | — | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00905021 | Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer(EXTENT) | terminated | Phase 1 / Phase 2 | 4 | Baylor Breast Care CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | terminated | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jul 16, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2021source: clinicaltrials